OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BPC.PL51

Birzeit Pharmaceutical Company Ltd

PharmaceuticalsVerified

Birzeit Pharmaceutical Company Ltd has a strong liquidity position, as evidenced by a current ratio of 8.37, indicating that the company holds significantly more current assets than current liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. However, the company reported negative operating and free cash flows of -$1,006,030 and -$1,331,630, respectively, which may signal short-term cash flow challenges. Profitability metrics show a negative return on equity (ROE) of -1.44% and a negative return on assets (ROA) of -1.19%, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. These figures are below the typical performance of the pharmaceutical industry, which generally expects positive ROE and ROA due to the high-margin nature of the sector. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. This lack of diversification may expose the company to higher operational and market risks if demand for its pharmaceutical products declines or if regulatory changes impact its operations. There is no geographic breakdown provided, but the company is based in Palestine, which may limit its exposure to international markets and increase regional economic and political risks. The company reported a net loss of -$1,441,470 in the latest period, and while no specific growth trajectory is provided, the negative net income and cash flows suggest a challenging operating environment. The absence of capital expenditures and the lack of a clear growth strategy may indicate a focus on cost control rather than expansion. Risk factors include the company's negative net income and cash flows, which could affect its ability to fund operations and invest in future growth. The company has no immediate filing-based liquidity or dilution flags, and dilution risk is assessed as low. However, the negative operating cash flow and net loss may raise concerns about the company's long-term financial stability. Recent events include the latest financial filing, which shows a net loss and negative cash flows. No recent earnings call transcripts or other material events are available in the provided data.

30-day price · BPC.PL-0.17 (-4.4%)
Low$3.60High$3.85Close$3.68As of4 Jun, 00:00 UTC
Profile
CompanyBirzeit Pharmaceutical Company Ltd
TickerBPC.PL
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

Birzeit Pharmaceutical Company Ltd has a strong liquidity position, as evidenced by a current ratio of 8.37, indicating that the company holds significantly more current assets than current liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. However, the company reported negative operating and free cash flows of -$1,006,030 and -$1,331,630, respectively, which may signal short-term cash flow challenges. Profitability metrics show a negative return on equity (ROE) of -1.44% and a negative return on assets (ROA) of -1.19%, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. These figures are below the typical performance of the pharmaceutical industry, which generally expects positive ROE and ROA due to the high-margin nature of the sector. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. This lack of diversification may expose the company to higher operational and market risks if demand for its pharmaceutical products declines or if regulatory changes impact its operations. There is no geographic breakdown provided, but the company is based in Palestine, which may limit its exposure to international markets and increase regional economic and political risks. The company reported a net loss of -$1,441,470 in the latest period, and while no specific growth trajectory is provided, the negative net income and cash flows suggest a challenging operating environment. The absence of capital expenditures and the lack of a clear growth strategy may indicate a focus on cost control rather than expansion. Risk factors include the company's negative net income and cash flows, which could affect its ability to fund operations and invest in future growth. The company has no immediate filing-based liquidity or dilution flags, and dilution risk is assessed as low. However, the negative operating cash flow and net loss may raise concerns about the company's long-term financial stability. Recent events include the latest financial filing, which shows a net loss and negative cash flows. No recent earnings call transcripts or other material events are available in the provided data.
Key takeaways
  • The company has a strong liquidity position with a current ratio of 8.37 and no long-term debt.
  • Negative ROE and ROA indicate poor profitability and asset utilization.
  • The company's revenue is concentrated in a single segment, increasing operational risk.
  • Negative net income and cash flows suggest a challenging operating environment.
  • No immediate liquidity or dilution risks are flagged, but financial performance is a concern.
  • --
  • **RATIONALES**:
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$9.1M
Gross profit$2.8M
Operating income$1.4M
Net income-$1.4M
R&D
SG&A
D&A
SBC
Operating cash flow-$1.0M
CapEx-$218.4k
Free cash flow-$1.3M
Total assets$121.0M
Total liabilities$20.6M
Total equity$100.4M
Cash & equivalents
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$45.5M$10.1M$12.1M$10.0M
FY-3$47.0M$8.8M$7.9M$4.1M
FY-2$43.1M$7.1M$6.1M$440.4k
FY-1$40.7M$7.6M$5.2M$3.1M
FY0$48.0M$10.7M$11.9M$9.1M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$112.0M$91.9M
FY-3$123.0M$102.6M
FY-2$125.1M$104.3M
FY-1$128.8M$104.2M
FY0$140.2M$114.6M
PeriodOCFCapExFCFSBC
FY-4$3.6M-$929.6k$10.0M
FY-3$5.2M-$3.6M$4.1M
FY-2$12.2M-$3.3M$440.4k
FY-1$7.0M-$1.5M$3.1M
FY0$2.3M-$2.3M$9.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$9.1M$1.4M-$1.4M-$1.3M
FQ-6$8.4M$1.7M$1.5M$1.6M
FQ-5$10.0M$2.7M$2.2M$2.3M
FQ-4$13.2M$1.8M$3.0M$2.6M
FQ-3$10.2M$2.0M$1.3M$171.7k
FQ-2$12.3M$3.1M$6.5M$6.4M
FQ-1$10.9M$1.9M$2.0M$2.2M
FQ0$14.6M$3.6M$2.1M$2.2M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$121.0M$100.4M
FQ-6$120.4M$98.3M
FQ-5$121.5M$99.0M
FQ-4$128.8M$104.2M
FQ-3$123.5M$101.7M$1.5M
FQ-2$131.5M$108.2M$1.7M
FQ-1$133.0M$109.2M
FQ0$140.2M$114.6M
PeriodOCFCapExFCFSBC
FQ-7-$1.0M-$218.4k-$1.3M
FQ-6$1.8M-$501.2k$1.6M
FQ-5$3.6M-$790.7k$2.3M
FQ-4$7.0M-$1.5M$2.6M
FQ-3-$548.7k-$1.4M$171.7k
FQ-2$2.0M-$1.9M$6.4M
FQ-1$1.5M-$2.1M$2.2M
FQ0$2.3M-$2.3M$2.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$100.4M
Net cash
Current ratio8.4
Debt/Equity0.0
ROA-1.2%
ROE-1.4%
Cash conversion70.0%
CapEx/Revenue-2.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricBPC.PLActivity
Op margin15.3%2.4% medp25 -91.8% · p75 12.5%top quartile
Net margin-15.9%1.2% medp25 -98.4% · p75 10.4%below median
Gross margin30.8%45.6% medp25 29.8% · p75 66.7%below median
CapEx / revenue-2.4%-5.2% medp25 -15.8% · p75 -1.7%above median
Debt / equity0.0%9.3% medp25 0.1% · p75 43.8%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-15 22:33 UTC#7e11503c
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 13:19 UTCJob: d51b68ae